These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30357339)

  • 1. Quantifying the contribution of four resistance mechanisms to ciprofloxacin MIC in Escherichia coli: a systematic review.
    van der Putten BCL; Remondini D; Pasquini G; Janes VA; Matamoros S; Schultsz C
    J Antimicrob Chemother; 2019 Feb; 74(2):298-310. PubMed ID: 30357339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal mutations that accompany qnr in clinical isolates of Escherichia coli.
    Vinué L; Hooper DC; Jacoby GA
    Int J Antimicrob Agents; 2018 Mar; 51(3):479-483. PubMed ID: 29360506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a rapid mismatch PCR method to detect gyrA and parC mutations in ciprofloxacin-resistant clinical isolates of Escherichia coli.
    Qiang YZ; Qin T; Fu W; Cheng WP; Li YS; Yi G
    J Antimicrob Chemother; 2002 Mar; 49(3):549-52. PubMed ID: 11864958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mutations of gyrA in ciprofloxacin resistant Escherichia coli strains].
    Eraç B; Gill A; Amyes SG; Gülay Z
    Mikrobiyol Bul; 2003; 37(2-3):125-30. PubMed ID: 14593893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of novel mutations involved in quinolone resistance in Escherichia coli isolated from imported shrimp.
    Nawaz M; Sung K; Kweon O; Khan S; Nawaz S; Steele R
    Int J Antimicrob Agents; 2015 May; 45(5):471-6. PubMed ID: 25631675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparison of MAMA PCR and SSCP PCR to study chromosomal resistance against Ciprofloxacin and Nalidixic acid in Escherichia coli and Klebsiella pneumoniae.
    Hashemi B; Abdollahi M; Rafiei A; Pormohammad A; Ahanjan M; Moghadaszadeh M; Rashidian S
    Microb Pathog; 2018 Jul; 120():181-186. PubMed ID: 29742463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of quinolone resistance mechanisms and associations to minimum inhibitory concentrations in quinolone-resistant Escherichia coli isolated from humans and swine in Denmark.
    Cavaco LM; Frimodt-Møller N; Hasman H; Guardabassi L; Nielsen L; Aarestrup FM
    Microb Drug Resist; 2008 Jun; 14(2):163-9. PubMed ID: 18500921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of plasmid-mediated quinolone resistance determinants among Escherichia coli isolated from food animals in Korea.
    Tamang MD; Nam HM; Chae MH; Kim SR; Gurung M; Jang GC; Jung SC; Lim SK
    Foodborne Pathog Dis; 2012 Dec; 9(12):1057-63. PubMed ID: 23186547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.
    Bansal S; Tandon V
    Int J Antimicrob Agents; 2011 Mar; 37(3):253-5. PubMed ID: 21236644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
    Gebru E; Damte D; Choi MJ; Lee SJ; Kim YH; Park SC
    Vet Microbiol; 2012 Jan; 154(3-4):384-94. PubMed ID: 21893387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Fluoroquinolone Resistance in Enterobacteriaceae Isolated from the Assiut University Hospitals, Egypt: A Comparative Study.
    Abdel-Rahim MH; El-Badawy O; Hadiya S; Daef EA; Suh SJ; Boothe DM; Aly SA
    Microb Drug Resist; 2019 May; 25(4):509-519. PubMed ID: 30457926
    [No Abstract]   [Full Text] [Related]  

  • 15. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation Supply and Relative Fitness Shape the Genotypes of Ciprofloxacin-Resistant Escherichia coli.
    Huseby DL; Pietsch F; Brandis G; Garoff L; Tegehall A; Hughes D
    Mol Biol Evol; 2017 May; 34(5):1029-1039. PubMed ID: 28087782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
    Yang J; Luo Y; Cui S; Wang W; Han L
    Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes.
    Miller K; O'Neill AJ; Chopra I
    J Antimicrob Chemother; 2002 Jun; 49(6):925-34. PubMed ID: 12039884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.